Celularity Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 123

Employees

  • Stock Symbol
  • CELU

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $2.48
  • (As of Tuesday Closing)

Celularity General Information

Description

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 170 Park Avenue
  • Florham Park, NJ 07039
  • United States
+1 (908)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 170 Park Avenue
  • Florham Park, NJ 07039
  • United States
+1 (908)

Celularity Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Celularity Stock Performance

As of 15-Jul-2025, Celularity’s stock price is $2.48. Its current market cap is $59.4M with 23.9M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.48 $2.24 $1.00 - $5.22 $59.4M 23.9M 198K -$2.64

Celularity Financials Summary

As of 31-Dec-2024, Celularity has a trailing 12-month revenue of $54.2M.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 115,695 115,695 106,102 211,590
Revenue 54,220 54,220 22,771 17,975
EBITDA (44,037) (44,037) (184,266) 23,276
Net Income (57,892) (57,892) (196,295) 14,192
Total Assets 132,682 132,682 143,889 401,066
Total Debt 68,836 68,836 65,417 65,588
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Celularity Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Celularity‘s full profile, request access.

Request a free trial

Celularity Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Celularity‘s full profile, request access.

Request a free trial

Celularity Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell ther
Drug Discovery
Florham Park, NJ
123 As of 2024

San Diego, CA
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Celularity Competitors (84)

One of Celularity’s 84 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fate Therapeutics Formerly VC-backed San Diego, CA
Arvinas Formerly VC-backed New Haven, CT
ImmunityBio Formerly VC-backed San Diego, CA
Century Therapeutics Formerly VC-backed Philadelphia, PA
Senti Bio Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 84 competitors. Get the full list »

Celularity Patents

Celularity Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023206330-A1 Cleavage resistant cd16 constructs and uses thereof Pending 11-Jan-2022
EP-4463474-A1 Cleavage resistant cd16 constructs and uses thereof Pending 11-Jan-2022
AU-2022257116-A1 Multi-layer amniotic tissue grafts and uses thereof Pending 13-Apr-2021
CA-3216040-A1 Multi-layer amniotic tissue grafts and uses thereof Pending 13-Apr-2021
US-20240245830-A1 Multi-layer amniotic tissue grafts and uses thereof Pending 13-Apr-2021 A61L27/3633
To view Celularity’s complete patent history, request access »

Celularity Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Celularity Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Celularity‘s full profile, request access.

Request a free trial

Celularity Investments & Acquisitions (5)

Celularity’s most recent deal was a Corporate Asset Purchase with Sequence LifeScience (Rebound Matrix) for . The deal was made on 09-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sequence LifeScience (Rebound Matrix) 09-Oct-2024 Corporate Asset Purchase Buildings and Property
GX Acquisition 16-Jul-2021 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Caricord 31-Aug-2018 Merger/Acquisition Laboratory Services (Healthcare)
Alliqua BioMedical (Biologic Wound Care Assets) 07-May-2018 Corporate Asset Purchase Buildings and Property
HLI Cellular Therpaeutics 31-May-2017 Merger/Acquisition Biotechnology
To view Celularity’s complete investments and acquisitions history, request access »

Celularity ESG

Risk Overview

Risk Rating

Updated June, 21, 2023

23.25 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,842

Rank

Percentile

Commercial Services

Industry

of 462

Rank

Percentile

Business Support Services

Subindustry

of 176

Rank

Percentile

To view Celularity’s complete esg history, request access »

Celularity FAQs

  • When was Celularity founded?

    Celularity was founded in 1998.

  • Where is Celularity headquartered?

    Celularity is headquartered in Florham Park, NJ.

  • What is the size of Celularity?

    Celularity has 123 total employees.

  • What industry is Celularity in?

    Celularity’s primary industry is Drug Discovery.

  • Is Celularity a private or public company?

    Celularity is a Public company.

  • What is Celularity’s stock symbol?

    The ticker symbol for Celularity is CELU.

  • What is the current stock price of Celularity?

    As of 15-Jul-2025 the stock price of Celularity is $2.48.

  • What is the current market cap of Celularity?

    The current market capitalization of Celularity is $59.4M.

  • What is Celularity’s current revenue?

    The trailing twelve month revenue for Celularity is $54.2M.

  • Who are Celularity’s competitors?

    Fate Therapeutics, Arvinas, ImmunityBio, Century Therapeutics, and Senti Bio are some of the 84 competitors of Celularity.

  • What is Celularity’s annual earnings per share (EPS)?

    Celularity’s EPS for 12 months was -$2.64.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »